$OVV · Ovintiv Inc.
Ovintiv filed its Q3 2026 10-Q, reporting revenue of $2.602B (+25.9% YoY), net income of $549M ($1.99 diluted EPS), and operating margin of 33.7%. The nine-month period includes $1.485B in non-cash ceiling test impairments and a $337M loss on divestitures. Long-term debt was cut from $5.202B to $3.588B through note repurchases and maturities.
- Q3 revenue of $2.602B, up 25.9% YoY from $2.066B, driven by higher product and service revenues.
- Q3 diluted EPS of $1.99 vs $0.57 in Q3 2025; net income of $549M vs $148M.
- Nine-month ceiling test impairments of $1.485B ($1.111B USA, $374M Canada) from lower 12-month trailing prices.
- Long-term debt reduced to $3.588B from $5.202B at year-end 2025, including $109M in note repurchases during Q3.
- Nine-month net income of $375M includes a $337M loss on divestitures; operating margin was 33.7% in Q3.
Extended-hours trading shows OVV at $66.41, down just 0.03% from the regular close of $66.43 — essentially flat, suggesting the strong Q3 earnings were largely priced in or offset by the nine-month impairment overhang.
The stark contrast between surging quarterly earnings and massive nine-month impairments captures the tension between strong operational execution and the accounting drag of SEC full-cost ceiling tests in a volatile commodity environment.
Ovintiv's 25.9% revenue growth and aggressive debt reduction ($1.6B+ in nine months) stand out among E&P peers, though the ceiling test impairments reflect the sector-wide challenge of reconciling acquisition premiums with SEC-mandated trailing-price accounting.
The $1.485B in nine-month ceiling test impairments, driven by declines in 12-month average trailing prices, signal vulnerability to sustained commodity price weakness. The NuVista acquisition assets were impaired because acquisition-date market prices exceeded the lower trailing prices used in the ceiling test.